Akshitkumar M Mistry1, Sumeeth V Jonathan2, Meredith A Monsour2, Bret C Mobley3, Stephen W Clark4, Paul L Moots4. 1. Department of Neurological Surgery, University of Louisville, Louisville, Kentucky, USA. 2. School of Medicine, Vanderbilt University, Nashville, Tennessee, USA. 3. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 4. Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract
BACKGROUND: We examined the effect of dexamethasone prescribed in the initial 3 postoperative weeks on survival, steroid dependency, and infection in glioblastoma patients. METHODS: In this single-center retrospective cohort analysis, we electronically retrieved inpatient administration and outpatient prescriptions of dexamethasone and laboratory values from the medical record of 360 glioblastoma patients. We correlated total dexamethasone prescribed from postoperative day (POD) 0 to 21 with survival, dexamethasone prescription from POD30 to POD90, and diagnosis of an infection by POD90. These analyses were adjusted for age, Karnofsky performance status score, tumor volume, extent of resection, IDH1/2 tumor mutation, tumor MGMT promoter methylation, temozolomide and radiotherapy initiation, and maximum blood glucose level. RESULTS: Patients were prescribed a median of 159 mg [109-190] of dexamethasone cumulatively by POD21. Every 16-mg increment (4 mg every 6 hours/day) of total dexamethasone associated with a 4% increase in mortality (95% confidence interval [CI] 1%-7%, P < .01), 12% increase in the odds of being prescribed dexamethasone from POD30 to POD90 (95% CI 6%-19%, P < .01), and 10% increase in the odds of being diagnosed with an infection (95% CI, 4%-17%, P < .01). Of the 175 patients who had their absolute lymphocyte count measured in the preoperative week, 80 (45.7%) had a value indicative of lymphopenia. In the POD1-POD28 period, this proportion was 82/167 (49.1%). CONCLUSIONS: Lower survival, steroid dependency, and higher infection rate in glioblastoma patients associated with higher dexamethasone administration in the initial 3 postoperative weeks. Nearly half of the glioblastoma patients are lymphopenic preoperatively and up to 1 month postoperatively.
BACKGROUND: We examined the effect of dexamethasone prescribed in the initial 3 postoperative weeks on survival, steroid dependency, and infection in glioblastoma patients. METHODS: In this single-center retrospective cohort analysis, we electronically retrieved inpatient administration and outpatient prescriptions of dexamethasone and laboratory values from the medical record of 360 glioblastoma patients. We correlated total dexamethasone prescribed from postoperative day (POD) 0 to 21 with survival, dexamethasone prescription from POD30 to POD90, and diagnosis of an infection by POD90. These analyses were adjusted for age, Karnofsky performance status score, tumor volume, extent of resection, IDH1/2 tumor mutation, tumor MGMT promoter methylation, temozolomide and radiotherapy initiation, and maximum blood glucose level. RESULTS: Patients were prescribed a median of 159 mg [109-190] of dexamethasone cumulatively by POD21. Every 16-mg increment (4 mg every 6 hours/day) of total dexamethasone associated with a 4% increase in mortality (95% confidence interval [CI] 1%-7%, P < .01), 12% increase in the odds of being prescribed dexamethasone from POD30 to POD90 (95% CI 6%-19%, P < .01), and 10% increase in the odds of being diagnosed with an infection (95% CI, 4%-17%, P < .01). Of the 175 patients who had their absolute lymphocyte count measured in the preoperative week, 80 (45.7%) had a value indicative of lymphopenia. In the POD1-POD28 period, this proportion was 82/167 (49.1%). CONCLUSIONS: Lower survival, steroid dependency, and higher infection rate in glioblastoma patients associated with higher dexamethasone administration in the initial 3 postoperative weeks. Nearly half of the glioblastoma patients are lymphopenic preoperatively and up to 1 month postoperatively.
Authors: Woo Jin Kim; Yun-Sik Dho; Chan-Young Ock; Jin Wook Kim; Seung Hong Choi; Soon-Tae Lee; Il Han Kim; Tae Min Kim; Chul-Kee Park Journal: J Neurooncol Date: 2019-04-13 Impact factor: 4.130
Authors: Christian C Apfel; Kari Korttila; Mona Abdalla; Heinz Kerger; Alparslan Turan; Ina Vedder; Carmen Zernak; Klaus Danner; Ritva Jokela; Stuart J Pocock; Stefan Trenkler; Markus Kredel; Andreas Biedler; Daniel I Sessler; Norbert Roewer Journal: N Engl J Med Date: 2004-06-10 Impact factor: 91.245
Authors: Kenneth L Pitter; Ilaria Tamagno; Kristina Alikhanyan; Amira Hosni-Ahmed; Siobhan S Pattwell; Shannon Donnola; Charles Dai; Tatsuya Ozawa; Maria Chang; Timothy A Chan; Kathryn Beal; Andrew J Bishop; Christopher A Barker; Terreia S Jones; Bettina Hentschel; Thierry Gorlia; Uwe Schlegel; Roger Stupp; Michael Weller; Eric C Holland; Dolores Hambardzumyan Journal: Brain Date: 2016-03-28 Impact factor: 13.501
Authors: Emmanuel Rios Velazquez; Raphael Meier; William D Dunn; Brian Alexander; Roland Wiest; Stefan Bauer; David A Gutman; Mauricio Reyes; Hugo J W L Aerts Journal: Sci Rep Date: 2015-11-18 Impact factor: 4.379
Authors: Amber J Giles; Marsha-Kay N D Hutchinson; Heather M Sonnemann; Jinkyu Jung; Peter E Fecci; Nivedita M Ratnam; Wei Zhang; Hua Song; Rolanda Bailey; Dionne Davis; Caitlin M Reid; Deric M Park; Mark R Gilbert Journal: J Immunother Cancer Date: 2018-06-11 Impact factor: 13.751